With my colleagues, I translate laboratory research into new immunologic therapies that can target these tumors. We are evaluating radiolabeled monoclonal antibody treatments in combination with cell-based therapies that may enhance their effectiveness. Our research has defined the standards of care used to treat neuroblastoma today.
I also expertly served as chair for the department’s quality assessment committee for many years and have overseen the development and implementation of dozens of strategies, changes, and enhancements to improve patient safety and satisfaction.
In addition to caring for patients and conducting research, I teach and mentor fellows. I am able to provide them with a unique viewpoint on rare diseases that are difficult to find at other institutions. It is gratifying for me to see them make their own contributions to our field.